These results advocate the considerable potential of targeting FSP1 as a promising therapeutic approach for HCC patients exhibiting upregulated expression of HDLBP or lncFAL, which also implies that targeting ferroptosis-suppressive lncRNAs could offer a novel therapeutic approach for HCC patients. The gene discussed is AIFM2; the disease is hepatocellular carcinoma.